Clinical trials: Neoplasms，Non-Small Cell Lung Cancer
Lung Cancer
High-Dose 3-Dimensional Conformal Radiation Therapy in Treating Patients With Inoperable Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Using computer systems that create a 3-dimensional picture of the tumor to plan treatment may enable doctors to provide more effective radiation therapy that will cause less damage to normal tissue.
- Trial name
- NCT00062335
- Testing
- radiation therapy
- Where
- 7 sites in Belgium, France and 1 more
- Volunteers
- 14 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Stage Non-small Cell Lung Cancer
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
The purpose of this study is to closely examine tumor and blood samples from patients treated with nivolumab and ipilimumab in order to try to identify why some patients with lung cancers respond and why some patients do not.
- Trial name
- NCT02350764
- Testing
- nivolumab, pilimumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
60% of all malignant diseases occur in patients who are 65 years or older. For these patients, aggressive treatments are often not suitable due to reduced life-expectancy, reduced general condition, comorbidities, and reduced…
- Trial name
- TIE (NCT00678964)
- Testing
- Erlotinib, Vinorelbine and Carboplatin
- Where
- 40 sites in Germany
- Volunteers
- 260 people
- Sponsor
- LungenClinic Grosshansdorf
Lung Cancer (NSCLC), Early Stage Lung Non-Small Cell Carcinoma
Interventional Ablation for Early-stage Lung Cancer
What is this study about? This clinical trial aims to compare two treatments for high-risk lung nodules or early-stage lung cancer: interventional ablation (a minimally invasive procedure that destroys tumors with heat or cold)…
- Trial name
- NCT07005999
- Where
- China
- Volunteers
- 656 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
EGFR Exon 20 Mutation, ERBB2 Gene Mutation
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent).
- Conditions
- EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03066206
- Testing
- Poziotinib
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
This is a Phase II, double-blind, randomized, multicenter trial designed to preliminarily evaluate the activity and safety of treatment with MetMAb + erlotinib versus erlotinib + placebo in second- and third-line Non-Small Cell…
- Trial name
- NCT00854308
- Testing
- Erlotinib HCl, MetMAb
- Volunteers
- 137 people
- Sponsor
- Genentech, Inc.
Non-Small-Cell Lung Carcinoma
Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
Phase II, randomised, controlled, non comparative study with 2 parallel groups: Arm A: patients will receive induction chemotherapy (cisplatin and docetaxel) followed by a concomitant radio-chemotherapy including 2 cycles of…
- Trial name
- NCT00985855
- Testing
- cisplatin, vinorlebine, cetuximab, cisplatine, etoposide, cetuximab
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Institut de Cancérologie de la Loire
Non-Small Cell Lung Cancer
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab…
- Trial name
- NCT00343291
- Testing
- Cetuximab, Bevacizumab, Paclitaxel
- Where
- 43 sites in United States
- Volunteers
- 121 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Head and Neck Cancer
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two centres on patients with advanced cancer expressing EGFR.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT00820417
- Testing
- Cetuximab/Gefitinib combination and/or monotherapy
- Where
- 2 sites in Belgium, Spain
- Volunteers
- 63 people
- Sponsor
- Harrison Clinical Research
Non Small Cell Lung Cancer
Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations
Lung cancer is the most common neoplastic disease globally, with over 2 million new cases annually, accounting for 11.6% of all cancer diagnoses. It remains the leading cause of cancer-related deaths.
- Trial name
- METLUNG (NCT05445791)
- Testing
- Metformin Hydrochloride
- Where
- Mexico
- Volunteers
- 312 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Non-Small Cell Lung Cancer
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
The primary purposes of this study are to find out if using high doses of the drug Gefitinib (Iressa) as a way to treat patients with non-small cell lung cancer that has spread to the covering of the brain and/or spinal cord…
- Trial name
- NCT00372515
- Testing
- Gefitinib
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- David M. Jackman, MD
Non-Small Cell Lung Cancer
Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer
A randomized phase II study to assess the efficacy and safety of Trastuzumab Rezetecan and/or Adebrelimab as consolidation therapy following chemoradiotherapy in patients with unresectable stage III HER2-altered NSCLC.
- Trial name
- NCT07836543
- Testing
- Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab, Trastuzumab Rezetecan (SHR-A1811), Adebrelimab
- Volunteers
- 105 people
- Sponsor
- Ming Chen
Non-small Cell Lung Cancer
Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data
This research will leverage machine learning (ML) and causal inference techniques applied to real-world data (RWD) to generate evidence that personalizes treatment strategies for patients with advanced non-small cell lung cancer…
- Trial name
- NCT06934343
- Where
- United States
- Volunteers
- 144,400 people
- Sponsor
- University of Utah
Unresectable Stage III Non-small Cell Lung Cancer
A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- NCT04111913
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
NSCLC
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
The goal of this clinical trial is to evaluate QL1706 plus bevacizumab with or without chemotherapy in patients with PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) previously…
- Trial name
- NCT07134413
- Testing
- QL1706 plus bevacizumab with or without chemotherapy
- Volunteers
- 77 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-Small-Cell Lung Carcinoma
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in participants with advanced or metastatic nonsquamous non-small cell…
- Trial name
- NCT02578680
- Testing
- Pembrolizumab 200 mg, Cisplatin, Carboplatin
- Volunteers
- 616 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
The main aim of this study is to evaluate the safety and tolerability of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Epidermal Growth Factor Receptor (EGFR) mutation(s)…
- Trial name
- NCT02044380
- Testing
- Afatinib
- Where
- 5 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
To compare the pairwise PK similarities between BAT3306, EU-Keytruda, and US-Keytruda, all administered with pemetrexed and carboplatin.
- Trial name
- NCT06280196
- Testing
- BAT3306, EU-Keytruda®, US-Keytruda®
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Bio-Thera Solutions
Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or…
- Conditions
- Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer
- Trial name
- NCT02567396
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Sponsor
- National Cancer Institute (NCI)
Stage IIIB or IV Non-Small Cell Lung Cancer
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin
- Trial name
- NCT00473889
- Testing
- vorinostat, Comparator: paclitaxel, Comparator: carboplatin
- Volunteers
- 253 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.